

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Consultancies: Stephanie Bass (Entasis); Mitchell S. Buckley (Wolters Kluwer); Chris Droege (Deloitte Consulting LLP); Eric Johnson (Slayback Pharmaceuticals); Patrick M. Wieruszewski (La Jolla Pharmaceutical Company); G. Christopher Wood (ASHP)

Stock Ownership:

Royalties:

Grants: Brittany Bissell (ASHP, University of Kentucky); Chris Droege (ACCP); Alexander H. Flannery (ACCP, American Society of Nephrology, La Jolla Pharmaceutical Company); Anthony Hawkins (University of Georgia College of Pharmacy); Heather P. May (ACCP, Mayo Clinic); Andrea Sikora Newsome (NIH); Joseph M. Swanson (Cubist/Merck)

Honoraria: Abby Bailey (ACCP EM PRN); Joseph M. Swanson (United Arab Emirates – Ministry of Health)

Other:

Nothing to disclose: Mahmoud A. Ammar, Paige Garber Bradshaw, Jennifer Falvey, Maria Guido, Leslie A. Hamilton, Sara Jordan Hyland, Heather A. Johnson, Debbie Liang, Brian P. Murray, Andrea M. Nei, Jaimini S. Patel, Michael A. Peters, Michael A. Rudoni, Poorvi Shah, Zachary R. Smith, Jaclyn Stoffel, Kyle A. Weant, Maggie Zhao

ROLE OF BPS: The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. CCSAP has been approved by BPS for use in BCCCP recertification. Information about the BPS recertification process is available [online](#).

Questions regarding BCCCP recertification should be directed to:

[Board of Pharmacy Specialties](#)

2215 Constitution Avenue NW

Washington, DC 20037

(202) 429-7591